### **U.S. PRODUCERS' QUESTIONNAIRE**

## ALKYL PHOSPHATE ESTERS ("PHOSPHATE ESTERS") FROM CHINA

This questionnaire must be received by the Commission by May 7, 2024

See last page for instructions regarding how to file this questionnaire.

The information called for in this questionnaire is for use by the United States International Trade Commission in connection with its antidumping and countervailing duty investigations concerning phosphate esters from China (Inv. Nos. 701-TA-721 and 731-TA-1689 (Preliminary)). The information requested in the questionnaire is requested under the authority of the Tariff Act of 1930, title VII. This report is mandatory and failure to reply as directed can result in a subpoena or other order to compel the submission of records or information in your firm's possession (19 U.S.C. § 1333(a)).

City			State		Zip Cod	le			
Website _									
Has your fir January 1, 2		sphate esters (as	defined on next	page) i	n the Uni	ted States at	t any time	since	
☐ NO	(Sign the cert	fication below and	promptly return <b>o</b> ı	<b>nly</b> this	page of th	e questionnai	re to the Co	mmission)	
YES	(Complete all	parts of the question	nnaire, and return	the en	tire questi	onnaire to the	e Commissio	on)	
link: https	://usitc.gov/qj	ortal. (PIN: FIR	E). See last pag	e for c	letailed	instruction	s.		
			CERTIFICATIO	N					
lge and belief	and understand	supplied in res	ation submitted	is subj	ect to au	dit and veri	fication by	y the Comr	nission.
ge and belief of this certific tion provided mission on the ndersigned, ac ing or other p el (a) for deve and evaluat ix 3; or (ii) by	and understand ation I also grin this question same or simila cknowledge that roceedings may loping or main tons relating to J.S. governmen	that the informant consent for naire and throug	ation submitted the Commission hout this procee bmitted in respondend used: (i) by the of this or a repersonnel, and contract personit	is subj , and ding ir onse to the Co clated   opera	ect to au its emplo any oth this rec ommissio proceedir tions of	dit and veri byees and c er import-in uest for inj n, its emplo ng, or (b) in the Commis	fication by contract po- jury proce formation yees and i internal ir ssion inclu	y the Comrersonnel, to endings con and throu Offices, and undersigation and and and and and and and and and an	mission. to use inducted aghout to ad contr ans, aud er 5 U.S
ge and belief of this certific tion provided mission on the ndersigned, ac ing or other p el (a) for deve and evaluat ix 3; or (ii) by	and understand ation I also grin this question same or similar same or similar coceedings may loping or main tons relating to J.S. governmen I sign appropria	that the informant consent for naire and through merchandise.  It information sube disclosed to aining the record the programs, temployees and	ation submitted the Commission hout this procee bmitted in responsion used: (i) by ds of this or a representation agreements.	is subj , and ding ir onse to the Co clated   opera	ect to au its emplo any oth this rec ommissio proceedir tions of	dit and veri byees and c er import-in uest for inj n, its emplo ng, or (b) in the Commis	fication by contract po- jury proce formation yees and i internal ir ssion inclu	y the Comrersonnel, to endings con and throu Offices, and undersigation and and and and and and and and and an	mission. to use inducted aghout to ad contr ans, aud er 5 U.S

#### PART I.—GENERAL INFORMATION

**Background.**--This proceeding was instituted in response to a petition filed on April 23, 2024, by ICL-IP America, Inc., St. Louis, Missouri. Antidumping and/or countervailing duties may be assessed on the subject imports as a result of these proceedings if the Commission makes an affirmative determination of injury, threat, or material retardation, and if the U.S. Department of Commerce ("Commerce") makes an affirmative determination of subsidization and/or dumping. Pertinent information to this proceeding is available at:

Questionnaires: <a href="https://usitc.gov/reports/active">https://usitc.gov/reports/active</a> import injury questionnaires. Other case information: <a href="https://ids.usitc.gov/case/8193/investigation/8556">https://ids.usitc.gov/case/8193/investigation/8556</a>.

*Phosphate esters* covered by this proceeding are based exclusively on side chains with a length of two or three carbon atoms (also includes chlorinated alkyl chains) and with a phosphorus content of at least 6.5 percent (per weight) and a viscosity between 1 and 2000 mPa.s (at 20-25 °C). Alkyl phosphate esters include Tris (2-chloroisopropyl) phosphate ("TCPP"), Tris(1,3-dichloroisopropyl) phosphate ("TDCP"), and Triethyl Phosphate ("TEP"). TCPP is also known as Tris (1-chloro-2- propyl) phosphate, Tris(1-chloropropan-2-yl) phosphate, Tris (monochloroisopropyl) phosphate ("TMCP"), and Tris(2-chloroisopropyl) phosphate ("TCIP"). It has the chemical formula  $C_9H_{18}Cl_3O_4P$  and the CAS Nos. 1244733-77-4 and 13674-84-5. It may also be identified as CAS No. 6145-73-9. TDCP is also known as Tris(1,3-dichloroisopropyl) phosphate, Tris (1,3-dichloro-2-propyl) phosphate, Chlorinated tris, Tris(2-chloro-1-(chloromethyl) ethyl) phosphate, TDCPP, and TDCIPP. It has the chemical formula  $C_9H_{15}Cl_6O_4P$  and the CAS No. 13674-87-8. TEP is also known as Phosphoric acid triethyl ester, phosphoric ester, flame retardant TEP, Tris(ethyl) phosphate, Triethoxyphosphine oxide, and Ethyl phosphate (neutral). It has the chemical formula  $(C_2H_5O)_3PO$  and the CAS No. 78-40-0. Also included in this investigation are isomers of the foregoing products and blends including one or more alkyl phosphate esters where the alkyl phosphate esters account for 20 percent or more of the blend by weight.

Phosphate esters are currently imported under statistical reporting number 2919.90.5050 of the Harmonized Tariff Schedule of the United States (HTSUS). They may also be imported under HTSUS statistical reporting numbers 2919.90.5010 and 3824.99.5000. The HTSUS provisions are for convenience and customs purposes; the written description of the scope is dispositive.

<u>Reporting of information</u>.--If information is not readily available from your records, provide carefully prepared estimates. If your firm is completing more than one questionnaire (i.e., a producer, importer, and/or purchaser questionnaire), you need not respond to duplicated questions.

<u>Confidentiality</u>.--The commercial and financial data furnished in response to this questionnaire that reveal the individual operations of your firm will be treated as confidential by the Commission to the extent that such data are not otherwise available to the public and will not be disclosed except as may be required by law (see 19 U.S.C. § 1677f). Such confidential information will not be published in a manner that will reveal the individual operations of your firm; however, general characterizations of numerical business proprietary information (such as discussion of trends) will be treated as confidential business information only at the request of the submitter for good cause shown.

<u>Verification</u>.--The information submitted in this questionnaire is subject to audit and verification by the Commission. To facilitate possible verification of data, please keep all files, worksheets, and supporting documents used in the preparation of the questionnaire response. Please also retain a copy of the final document that you submit.

**Release of information**.--The information provided by your firm in response to this questionnaire, as well as any other business proprietary information submitted by your firm to the Commission in connection with this proceeding, may become subject to, and released under, the administrative protective order provisions of the Tariff Act of 1930 (19 U.S.C. § 1677f) and section 207.7 of the Commission's Rules of Practice and Procedure (19 CFR § 207.7). This means that certain lawyers and other authorized individuals may temporarily be given access to the information for use in connection with this proceeding or other import-injury proceedings conducted by the Commission on the same or similar merchandise; those individuals would be subject to severe penalties if the information were divulged to unauthorized individuals.

In addition, if your firm is a U.S. producer, the information you provide on your production and imports of phosphate esters and your responses to the questions in Part I of the producer questionnaire will be provided to the U.S. Department of Commerce, upon its request, for use in connection with (and only in connection with) its requirement pursuant to section 702(c)(4)/732(c)(4) of the Act (19 U.S.C. § 1671a(c)(4)/1673a(c)(4)) to make a determination concerning the extent of industry support for the petition requesting this proceeding. Any information provided to Commerce will be transmitted under the confidentiality and release guidelines set forth above. Your response to these questions constitutes your consent that such information be provided to Commerce under the conditions described above.

<u>D-GRIDs tool.</u>--The Commission has a tool that firms can use to move data from their own MS Excel compilation files into self-contained data tables within this MS Word questionnaire, thereby reducing the amount of cell-by-cell data entry that would be required to complete this form. This tool is a macroenabled MS Excel file available for download from the Commission's generic questionnaires webpage (<a href="https://www.usitc.gov/trade\_remedy/question.htm">https://www.usitc.gov/trade\_remedy/question.htm</a>) called the "D-GRIDs tool." Use of this tool to help your firm complete this questionnaire is <u>optional</u>. Firms opting to use the D-GRIDs tool to populate their data into this questionnaire will need the D-GRIDs specification sheet PDF file specific to this proceeding (available on the case page which is linked under the "Background" above) which includes the necessary references relating to this questionnaire, as well as the macro-enable MS Excel D-GRIDs tool itself from the generic questionnaires page. More detailed instructions on how to use the D-GRIDs tool are available within the D-GRIDs tool itself.

I-1a. Reporting requirements.--Please report below the actual number of hours required and the cost to your firm of completing this questionnaire for use by the Office of Management and Budget.

Hours	Dollars

Public reporting burden for this questionnaire is estimated to average 55 hours per response, including the time for reviewing instructions, gathering data, and completing and reviewing the questionnaire.

We welcome comments regarding the accuracy of this burden estimate, suggestions for reducing the burden, and any suggestions for improving this questionnaire. Please provide such comments to the Office of Investigations, <a href="mailto:import injury@usitc.gov">import injury@usitc.gov</a>.

I-1b.	TAA information releaseIn the event that the U.S. International Trade Commission (USITC)
	makes an affirmative final determination in this proceeding, do you consent to the USITC's
	release of your contact information (company name, address, contact person, contact person's
	title, telephone number, email address) appearing on the front page of this questionnaire to the
	Departments of Commerce, Labor, and Agriculture, as applicable, so that your firm and its
	workers can be made eligible for benefits under the Trade Adjustment Assistance program?

Yes	☐ No
-----	------

I-2a. <u>Establishments covered</u>.--Provide the city, state, zip code, and brief description of each establishment covered by this questionnaire. Firms operating more than one establishment should combine the data for all establishments into a single report.

"<u>Establishment</u>"--Each facility of a firm involved in the <u>production</u> of phosphate esters, including auxiliary facilities operated in conjunction with (whether or not physically separate from) such facilities.

Establishments covered <sup>1</sup>	City, State	Zip (5 digit)	Description
1			
2			
3			
4			
5			
6			
<sup>1</sup> Additional discussion on establishments consolidated in this questionnaire:			

I-2b.	Stock symbol information If your firm or parent firm is publicly traded, please specify the
	stock exchange and trading symbol:

I-2c. <u>External counsel.</u>— If your firm or parent firm is represented by external counsel in relation to this proceeding, please specify the name of the law firm and the lead attorney(s).

Law firm:	
Lead attorney(s):	

I-3. <u>Petitioner status.</u>--Is your firm a petitioner in this proceeding or a member firm of the petitioning entity?

No	Yes	

I-4. Petition support.--Does your firm support or oppose the petition?

Country	Investigation type	Support	Oppose	Take no position
China	Antidumping duty			
China	Countervailing duty			

		Phosphate Esters (Preliminary)	Page		
-5.	OwnershipIs your firm owned, in whole or in part, by any other firm?  ☐ No ☐ YesList the following information, relating to the ultimate parent/own				
	Firm name	Country	Extent of ownership (percent)		
hat s or joir	olely or jointly owned, ma	naged, or otherwise controlled y otherwise controlled by a firm that	anaged, or otherwise controlled; a firm our firm; and/or a firm that was solely at also solely or jointly owned, managed		
-6.	Related importers/exp foreign, that are engage	ortersDoes your firm have any	related firms, either domestic or from China into the United States or ina to the United States?		
	□ No □ Yes	-List the following information.			
	Firm name	Country	Affiliation		
-7.	engaged in the product	es your firm have any related firm ion of phosphate esters? List the following information.	ms, either domestic or foreign, that are		
	Firm name	Country	Affiliation		

## PART II.--TRADE AND RELATED INFORMATION

Further information on this part of the questionnaire can be obtained from Celia Feldpausch (202-205-2387, celia.feldpausch@usitc.gov). Supply all data requested on a calendar-year basis.

II-1.	<u>Contact information</u> Please identify the responsible individual and the manner by which
	Commission staff may contact that individual regarding the confidential information submitted
	in Part II.
	T.,

Name	
Title	
Email	
Telephone	

II-2a. <u>Changes in operations.</u>—Please indicate whether your firm has experienced any of the following changes in relation to the production of phosphate esters since January 1, 2021.

		If checked, please describe the nature, timing / duration, and impact on operations of any such reported changes as well as the business reasons for them; leave completely blank if not applicable
	Plant openings	
	Plant closings	
	Prolonged shutdowns	
	Production curtailments	
	Relocations	
	Expansions	
	Acquisitions	
	Consolidations	
	Weather-related or force majeure events	
	Other (e.g., revised labor agreements, technology)	

II-2b. **COVID-19 pandemic.**—Has the COVID-19 pandemic or have any government actions taken to contain the spread of the COVID-19 virus resulted in changes in your firm's supply chain arrangements, production, employment, and shipments relating to phosphate esters? In your response, please discuss the duration and timing of any such changes as they relate to your firm's operations.

No	If yes, describe these changes including the impact over time on the (a) supply chain, (b) production and shipments, and (c) employment with respect to phosphate esters.

II-3a. **Production using same machinery.--**Please report your firm's production of products using the same equipment, machinery, or employees as used to produce phosphate esters, and the combined capacity (both installed and practical capacity) on this shared equipment, machinery, or employees in the periods indicated.

"Installed overall capacity" – The level of production that your establishment(s) could have attained, assuming your firm's optimal product mix, and based solely on existing capital investments, i.e., machinery and equipment that is in place and ready to operate. This capacity measure does <u>not</u> take into account other constraints to production such as existing workforce constraints, availability of raw materials, or downtime for maintenance, repair, and clean-up. This capacity measure is sometimes referred to as "nameplate" or "theoretical" capacity.

"Practical overall capacity" – The level of production that your establishment(s) could reasonably have expected to attain, taking into account your firm's actual product mix over the period. This capacity measure is based on not only existing capital investments, i.e., machinery and equipment that is in place and ready to operate; but also non-capital investment constraints, such as (1) normal operating conditions, including normal downtime for maintenance, repair, and cleanup; (2) your firm's existing in place and readily available labor force; (3) availability of material inputs; and (4) any other constraints that may have limited your firm's ability to produce the reported products. Importantly, this capacity measure is the maximum "practical" production your firm could have achieved without hiring new personnel or expanding the number of shifts operated in the period.

"Practical phosphate esters capacity" – The level of production of phosphate esters that your establishment(s) could reasonably have expected to attain. The same assumptions apply to this capacity measure as for practical overall capacity, but only includes the portion of practical overall capacity allocated to the production of phosphate esters based on the actual product mix experienced over the period.

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

Takes into account	Installed overall capacity	Practical overall capacity	Practical phosphate esters capacity
Existing capital investments	Yes	Yes	Yes
Product mix	Yes	Yes	Yes
Normal downtime, maintenance, repair and clean-up	No	Yes	Yes
Existing labor force	No	Yes	Yes
Availability of material inputs	No	Yes	Yes
Actual number of shifts and hours operated	No	Yes	Yes
Limited to phosphate esters	No	No	Yes

#### II-3a. **Production using same machinery.**—**Continued**

Quantity (in metric tons)			
	Calendar year		
Item	2021	2022	2023
Capacity measures: Installed overall capacity <sup>1</sup>			
Practical overall capacity <sup>12</sup>			
Practical phosphate esters capacity <sup>3 4</sup>	0	0	0
Production of: Phosphate esters <sup>3 4</sup>	0	0	0
Other products <sup>5</sup>			
Total production using same machinery or workers	0	0	0

<sup>&</sup>lt;sup>1</sup> Data reported for both "installed overall" and "practical overall" capacity should each individually be greater than data reported for total production (last line). Additionally, data reported for "installed overall" capacity should be greater than "practical overall" capacity in every period.

<sup>&</sup>lt;sup>2</sup> Please provide details in your response to the question on capacity constraints in question II-3d below that explain the differences reported between "installed" overall capacity and "practical" overall capacity.

<sup>&</sup>lt;sup>3</sup> Data for this indicator will populate here once reported below in question II-8.

<sup>&</sup>lt;sup>4</sup> Data reported for practical phosphate esters capacity should be greater than the data reported for production of phosphate esters in each period, if not revise prior to submission to the Commission. Additionally, if your firm reports the production of no other products on the same machinery and using the same workers as phosphate esters then "practical overall" and "practical phosphate esters" capacity measures should be equal to each other.

<sup>&</sup>lt;sup>5</sup> Please identify these products: \_\_\_\_\_

## II-3b. Production capability and actual production of phosphate esters.

## (a) TCPP

Item	(Check one)	Explanation
Able to produce and		Indicate the quantity of TCPP actually produced (metric tons)
actually produced		in 2023: .
Able to produce, but		Indicate the reasons your firm did not produce TCPP despite
did not actually		having the technical capabilities to do so:
produce		
		Indicate the technical reasons your firm is unable to produce
		TCPP with your existing capital investments: .
Not able to produce		
		Specify how much new investment it would take for your firm
		to be able to produce TCPP: .

## (b) TDCP

Item	(Check one)	Explanation
Able to produce and	<u></u>	Indicate the quantity of TDCP actually produced (metric tons)
actually produced		in 2023: .
Able to produce, but		Indicate the reasons your firm did not produce TDCP despite
did not actually		having the technical capabilities to do so:
produce		
		Indicate the technical reasons your firm is unable to produce
		TDCP with your existing capital investments: .
Not able to produce		
		Specify how much new investment it would take for your firm
		to be able to produce TDCP:

## (c) TEP

Item	(Check one)	Explanation
Able to produce and actually produced		Indicate the quantity of TEP actually produced (metric tons) in 2023:
Able to produce, but did not actually produce		Indicate the reasons your firm did not produce TEP despite having the technical capabilities to do so:
Not able to produce		Indicate the technical reasons your firm is unable to TEP with your existing capital investments:  Specify how much new investment it would take for your firm to be able to produce TEP:

	Hours per week	Weeks per year		
Capacity calculationsPlease describe the methodology used to calculate <i>installed</i> and <i>practical</i>				

II-3e. Practical overall capacity constraints.--Please describe the constraint(s) that set the limit(s) on your firm's practical overall capacity over the period reported in question II-3a. If different constraints were binding over different periods reported, please specify when each constraint was limiting your reported practical overall capacity. If a constraint was not actually binding over the period reported, but was still a constraint to achieving the installed capacity level, indicate at what level it would have been binding.

Constraint (check as many as appropriate)		<b>Description</b> (If checked, please describe the details, timing, and duration of the constraint; leave completely blank if not applicable)
	Production bottlenecks	
	Existing labor force	
	Supply of material inputs	
	Fuel or energy	
	Storage capacity	
	Logistics/transportation	
	Other constraints (list the specific constraints in the description field)	

	mstalled (	overall capacity reported in II-3a.
		erall capacityTo the extent that your company is reporting excess installe
of produc	ction) wou	ease report, with specificity: (1) which machines or equipment (or other ele Ild need to be brought back into production for your plant to operate at full
		ne specific dates on which such machines or equipment were last used by yo hosphate esters.
		<u> </u>
Products	shifting —	
	shifting.—	
(a) Is	s your firm	n able to switch production (capacity) between phosphate esters and other sing the same equipment and/or labor?
(a) Is	s your firm	n able to switch production (capacity) between phosphate esters and other sing the same equipment and/or labor?
(a) Is	s your firm	a able to switch production (capacity) between phosphate esters and other sing the same equipment and/or labor?  If yes—(i.e., have produced other products or are able to produce other
(a) Is p	Yes	a able to switch production (capacity) between phosphate esters and other sing the same equipment and/or labor?  If yes—(i.e., have produced other products or are able to produce other

II-5.	Capacity checklistPlease check that the capacity numbers reported in question II-3a follow the
	Commission's relevant definitions for capacity.

Item	√ if Yes
Are all three capacity measures reported based on <u>currently installed</u> <u>machinery and equipment</u> (i.e., the reported capacity level would not require additional capital investments in order to achieve)?	
Are practical overall capacity and practical phosphate esters capacity measures reported based on <i>existing labor force</i> (i.e., the reported capacity level would not require hiring additional production related workers or adding shifts)?	
Are practical overall capacity and practical phosphate esters capacity measures based on <i>the actual <u>availability of material inputs</u>?</i>	
Do both practical overall capacity and practical phosphate esters capacity measures account for <u>normal downtime, maintenance, repair and clean-up</u> activities?	
Does the difference between practical overall capacity and practical phosphate esters capacity equal the portion of practical overall capacity that is dedicated to the production of out-of-scope products?	

Note: If your firm is not able to answer "yes" to any of the above criteria as it relates to your firm's reported capacity levels, please revise your capacity numbers to be in conformance with the appropriate definition prior to submission to the Commission.

II-6. <u>Tolling</u>.--Since January 1, 2021, has your firm been involved in a toll agreement regarding the production of phosphate esters?

"Toll agreement"-- Agreement between two firms whereby the first firm ("tollee") furnishes the raw materials and the second firm ("toller") uses the raw materials to produce a product that it then returns to the first firm with a charge for processing costs, overhead, etc.

No	Yes	
		If yes—Please complete the table below.

Does your firm act as the toller or tollee in this arrangement?	Toller:	Tollee:
Report the share of your firm's production of phosphate esters that in this toll arrangement in 2023.	t was included	%
Please describe the activities performed in this tolling arrangement	:	
Please indicate the name(s) of the firm(s) involved:		

II-7.	<b>Foreign</b>	trade	zones

(a) <u>Firm's FTZ operations</u>.--Does your firm produce phosphate esters in and/or admit phosphate esters into a foreign trade zone (FTZ)?

**"Foreign trade zone"** is a designated location in the United States where firms utilize special procedures that allow delayed or reduced customs duty payments on foreign merchandise. A foreign trade zone must be designated as such pursuant to the rules and procedures set forth in the Foreign-Trade Zones Act.

No	If yesDescribe the nature of your firm's operations in FTZs and identify the specific FTZ site(s).

(b) Other firms' FTZ operations.--To your knowledge, do any firms in the United States import phosphate esters into a foreign trade zone (FTZ) for use in distribution of phosphate esters and/or the production of downstream articles?

No	Yes	If yesIdentify the firms and the FTZs.	

II-8. **Production, shipments, and inventory data.--**Report your firm's uses (shipment or storage) of domestically produced phosphate esters during the specified periods.

"Production" – All production in your U.S. establishment(s), including production consumed internally within your firm and production for another firm under a toll agreement.

"Commercial U.S. shipments" – Shipments made within the United States as a result of an arm's length commercial transaction in the ordinary course of business. Report <u>net values</u> (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods) in U.S. dollars, f.o.b. your point of shipment.

"Internal consumption" – Product consumed internally by your firm. Such transactions are valued at fair market value.

"Transfers to related firms" – Shipments made to related firms. Such transactions are valued at fair market value.

"Related firm" —A firm that your firm solely or jointly owned, managed, or otherwise controlled; a firm that solely or jointly owned, managed, or otherwise controlled your firm; and/or a firm that was solely or jointly owned, managed, or otherwise controlled by a firm that also solely or jointly owned, managed, or otherwise controlled your firm.

"Export shipments" – Shipments to destinations outside the United States, including shipments to related firms.

"Inventories" — Finished goods inventory, not raw materials or work-in-progress.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the trade data, as Commission staff may contact your firm regarding questions on the trade data. The Commission may also request that your company submit copies of the supporting documents/records (such as production and sales schedules, inventory records, etc.) used to compile these data.

#### II-8. Production, shipment, and inventory data.--Continued

Quantity (in metric tons) and value (in \$1,000)				
	Calendar year			
Item	2021	2022	2023	
Practical phosphate esters capacity¹ (quantity) (A)				
Beginning-of-period inventories (quantity) (B)				
Production (quantity) (C)				
U.S. shipments: Commercial shipments: Quantity (D)				
Value (E)				
Internal consumption: <sup>2</sup> Quantity (F)				
Value² (G)				
Transfers to related firms: <sup>2</sup> Quantity (H)				
Value² (I)				
Export shipments: <sup>3</sup> Quantity (J)				
Value (K)				
End-of-period inventories (quantity) (L)				
<sup>1</sup> Report your firm's practical phosphate est question II-3a. <sup>2</sup> Internal consumption and transfers to rela different basis for valuing these transactions in	ted firms must be v	valued at fair market value. ase specify that basis (e.g., o	If your firm uses a	

RECONCILIATION OF SHIPMENTS, PRODUCTION, AND INVENTORY.--Generally, the data reported for the end-of-period inventories (i.e., line L) should be equal to the beginning-of-period inventories (i.e., line B), plus production (i.e., line C), less total shipments (i.e., lines D, F, H, and J). Please ensure that any differences are not due to data entry errors in completing this form, but rather reflect your firm's actual records; and also provide explanations for any differences (e.g., theft, loss, damage, record systems issues, etc.) if they exist.

	Calendar year			
Reconciliation	2021	2022	2023	
B + C - D - F - H - J - L = should equal				
zero ("0") or provide an explanation.1	0	0	0	

<sup>&</sup>lt;sup>1</sup> Explanation if the calculated fields above are returning values other than zero (i.e., "0") but are nonetheless accurate:\_

<sup>.</sup> However, the data provided above in this table should be based on fair market value.

<sup>&</sup>lt;sup>3</sup> Identify your firm's principal export markets: \_\_\_\_\_.

II-9. <u>Channels of distribution</u>.--Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) of U.S.-produced phosphate esters by channel of distribution during the specified periods.

Quantity (in metric tons)					
Calendar year					
Item 2021 2022 2023					
U.S. shipments:	J.S. shipments:				
to Distributors (M)					
to End users (N)					

<u>RECONCILIATION OF CHANNELS</u>.--Please ensure that the quantities reported for channels of distribution (i.e., lines M and N) in each time period equal the quantity reported for U.S. shipments (i.e., lines D, F, and H) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year			
Reconciliation	2021	2022	2023	
M + N - D - F - H = zero ("0"), if not				
revise.	0	0	0	

II-10. <u>U.S. shipments by product type</u>.-- Report your firm's U.S. shipments (i.e., inclusive of commercial U.S. shipments, internal consumption, and transfers to related firms) by product type during the specified periods.

<u>TCPP</u>.--Tris(2-chloroisopropyl) phosphate. It has the chemical formula  $C_9H_{18}Cl_3O_4P$  and CAS Nos. 1244733-77-4, 6145-73-9, and 13674-84-5.

<u>TDCP</u>.--Tris(1,3-dichloroisopropyl) phosphate. It has the chemical formula  $C_9H_{15}Cl_6O_4P$  and CAS No. 13674-87-8.

**TEP**.--Triethyl Phosphate. It has the chemical formula (C<sub>2</sub>H<sub>5</sub>O)<sub>3</sub>PO and CAS No. 78-40-0.

Quantity (in metric tons) and Value (in \$1,000)				
		Calendar year		
Item	2021	2022	2023	
U.S. shipments: TCPP:				
Quantity (O)				
Value (P)				
TDCP: Quantity (Q)				
Value (R)				
TEP:				
Quantity (S)				
Value (T)				

<u>RECONCILIATION OF U.S. SHIPMENTS BY PRODUCT TYPE.</u>--Please ensure that the quantities and values reported (i.e., lines O through T) in this question equal the quantities and values reported for U.S. shipments (i.e., lines D through I) in each time period. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year			
Reconciliation item	2021	2022	2023	
O + Q + S - D - F - H = zero ("0"), if not revise.	0	0	0	
P + R + T - E - G - I = zero ("0"), if not revise.	0	0	0	

Explanation of trends:

II-11. <u>Employment data</u>.--Report your firm's employment-related data related to the production of phosphate esters in your U.S. establishments and provide an explanation for any trends in these data.

"Production and Related Workers" (PRWs) includes working supervisors and all nonsupervisory workers (including group leaders and trainees) engaged in fabricating, processing, assembling, inspecting, receiving, storage, handling, packing, warehousing, shipping, trucking, hauling, maintenance, repair, janitorial and guard services, product development, auxiliary production for plant's own use (e.g., power plant), recordkeeping, and other services closely associated with the above production operations.

Average number employed may be computed by adding the number of employees, both full time and part time, for the 12 pay periods ending closest to the 15th of the month and divide that total by 12.

"Hours worked" includes time paid for sick leave, holidays, and vacation time. Include overtime hours actually worked; do not convert overtime pay to its equivalent in straight time hours.

"Wages paid" – Total wages paid before deductions of any kind (e.g., withholding taxes, old-age and unemployment insurance, group insurance, union dues, bonds, etc.). Include wages paid directly by your firm for overtime, holidays, vacations, and sick leave.

	Calendar year			
Item	2021	2022	2023	
Average number of PRWs (number)				
Hours worked by PRWs (1,000 hours)				
Wages paid to PRWs (\$1,000)				

Transfers to related firmsIf your firm reported transfers to related firms in question II-8, please identify the firm(s) and indicate the nature of the relationship between your firm and the related firms (e.g., joint venture, wholly owned subsidiary), whether the transfers were priced at market value or by a non-market formula, whether your firm retained marketing rights to all transfers, and whether the related firms also processed inputs from sources other than your firm.

II-13.	PurchasesHas your firm purchased phosphate esters produced in the United States or in other
	countries since January 1, 2021? (Do not include imports for which your firm was the importer
	of record. These should be reported in an importer questionnaire.)

"Purchase" – A transaction to buy product from a U.S. corporate entity such as another U.S. producer, a U.S. distributor, or a U.S. firm that has directly imported the product.

"Import" —A transaction to buy from a foreign supplier where your firm is the importer of record.

No	If yesReport such purchases in the table below and explain the reasons for your firms' purchases.

*Note*: If your firm served as the importer of record for any purchases from foreign suppliers, either for your own account or as a service for another entity, those purchases are to be considered "imports" not "purchases" and **should not** be included in the table below

(Q	uantity <i>in metric</i>	tons)			
	Calendar year				
Item	2021	2022	2023		
Purchases from U.S. importers of phosphate esters from— China					
All other sources <sup>1</sup>					
Purchases from domestic producers <sup>2</sup>					
Purchases from other sources <sup>3</sup>					
<sup>1</sup> Please list the name of the nonsubject im <sup>2</sup> Please list the name of the U.S. producer					

<sup>3</sup> Please list the name of the firm(s) from which your firm purchased this product: \_

II-14. Purchases of imports from China.--If your firm reported purchases from U.S. importers of phosphate esters from China at any time since January 1, 2021, report those purchases by the individual importer of record and subject source.

# **Purchases of imports from China**

Quantity (in metric tons)								
	Calendar year							
Importer of record	2021	2022	2023					
Grand total:	0	0	0					

#### II-14. Purchases of imports from China.—Continued.

<u>RECONCILIATION OF PURCHASES FROM CHINA</u>.--Please ensure that the quantities reported for your firms purchases of imports from China reported in this question (i.e., "total purchases of imports from China") in each time period equal the quantity reported for your firm's purchases from China in each time period in the previous question. If the calculated fields below return values other than zero (i.e., "0"), the data reported must be revised prior to submission to the Commission.

	Calendar year						
Reconciliation	2021	2022	2023				
Purchases from China in this table							
– purchases from China in previous							
table = zero ("0"), if not revise.	0	0	0				

II-15. Imports.--Since January 1, 2021, has your firm imported phosphate esters?

"Importer" – The person or firm primarily liable for the payment of any duties on the merchandise, or an authorized agent acting on his behalf.

No	Yes	
		If yes <u>COMPLETE AND RETURN A U.S. IMPORTERS' QUESTIONNAIRE</u>

II-16.	Other explanationsIf your firm would like to further explain a response to a question in Part II for which a narrative box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section.

## PART III.--FINANCIAL INFORMATION

Other (specify):

Address questions on this part of the questionnaire to Jennifer Brinckhaus (202-205-3188, jennifer.brinckhaus@usitc.gov).

<u>ennite</u>	<u>er.brinck</u>	haus@usit	c.gov).								
II-1.		ission staff	ion.—Please ic may contact tl	-		•					
	Name										
	Title										
	Email										
	Teleph	one									
II-2.	Accou	nting syste	<u>m</u> .—Briefly des	scribe	your 1	firm's f	inancial	ассо	unting syste	m.	
	A.1.		es your firm's f			-					
		If your fir	m's fiscal year	change	ed sin	ce Jani	uary 1, 20	021,	explain belo	ow:	
	A.2.	questions year basis based dat provided or on a fis	ancial data are III-9a, III-9a, III on the III-9a, III-9d, III on the III-9d,	l-12a, denson ole. Ple year ba	and II ne or ase ir asis (i	II-13a). provid ndicate ncludir ot aligr	Howeve les result whether ng firms was with the	r, if s that r the with e cal	providing the at are not release results in the a calendar-y	is data on a liable, fiscal nis section a rear based f	<u>calendar-</u> <u>-year</u> ire iscal year)
	B.1.		the lowest leve statements are			-			•	ny-wide) fo	r which
	B.2.	Does you	r firm prepare	profit/	loss s No	tateme	ents for p	hos	phate esters	:	
	B.3. Please indicate the type and frequency (if applicable) of financial st by your firm. Please check relevant items below.									atements p	repared
									Frequ	uency	
					Chec	k all				Semi-	
			cial statement	is	that	apply	Month	ly	Quarterly	annually	Annually
		Audited									
		Unaudit			<u> </u>						
		Annual r	•		Ļ	_					
			ns 10-K / 10-Q		<u> </u>						
		SEC Forr	n 20-F		L						

B.4. Please indicate the primary accounting basis used by your firm.

Accounting basis	Check one
U.S. GAAP	
IFRS	
Tax – cash	
Tax – accrual	
Other (specify):	

III-3. <u>Cost accounting system.</u> —Briefly describe your firm's cost accounting system (e.g. cost, job order cost, etc.).				

III-4. **Product listing.**—Please list the products your firm produces in the facilities in which it produces phosphate esters and provide the share of net sales accounted for by these products in 2023.

Products	Share of sales in 2023
Phosphate esters	%
	%
	%
	%
	%

U.S. Pr	oducers' Q	uestionnai	re – <b>Phosp</b> l	hate Esters (Preliminary)			Page 26
III-5.	or any ser	vices) use of transact	d in the pro	—Does your firm purchase <b>in</b> induction of phosphate esters en related firms, divisions an	from any rel	ated supplie	ers (e.g.,
	YesC	Continue to	question I	II-6. NoContinue to	o question III-	·8a.	
III-6.	<u>Inputs from related suppliers.</u> —Please identify the inputs used in the production of phosphate esters that your firm purchases from related suppliers and that are reflected in question III-9a. For "Share of total COGS" please report this information by relevant input for 2023.						
	Input			Related supplier		Share of t	
	-						%
							%
							%
							%
	the narrat		Purchase c	ost valuation method		Check all	that apply
	Related	supplier's				Г	
	Cost plus						
			r price to a	pproximate fair market value	9		
	Other (s			• •			
	If the methods used differ by input, please describe:						
III-7b.	b. Valuation method used for inputs from related suppliers.—Please confirm that the inputs purchased from related suppliers, as identified in III-6, were reported in III-9a (financial results on phosphate esters) in a manner consistent with the firm's accounting books and records.						
	Yes	No	If no—Pro	vide an explanation and the n III-9a.	valuation bas	sis used for	these inputs
		•	•				

III-8. Cost assignment/allocation basis.—Briefly describe the assignment/allocation bases used by your firm to assign the costs and expenses listed below for phosphate esters in the normal course of business and in the financial results reported in question III-9a (e.g., actual costs, standard costs, percentage of COGS, percentage of sales, etc.).

	Assignment/allocation bases used for phosphate esters—		
Cost/expense	In the normal course of business	In the financial results at III-9a	
Raw materials			
Direct labor			
Other factory costs			
SG&A expenses			
Interest expense			
Other income/expenses			

III-9a. <u>Operations on phosphate esters</u>.—Report the revenue and related cost information requested below on the phosphate esters operations of your firm's U.S. establishment(s). Include only sales (whether domestic or exports) and costs related to your U.S. manufacturing operations. <u>Do not</u> report any revenue or cost data related to the resale of purchased product.

**Net sales**—Report all commercial sales, internal consumption, and transfers to related firms, whether these are domestic sales or exports. Report net sales values less discounts, returns, allowances, and prepaid freight, in U.S. dollars, f.o.b. your point of shipment. The freight costs associated with delivering the product to your customer should not be included.

Note: If the financial data are reported on a calendar-year basis, the total net sales quantities and values should match the total shipment quantities and values reported in Part II of this questionnaire (see question III-14 for a reconciliation grid).

**Internal consumption**—Product consumed internally by your firm. Report internal consumption at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

**Transfers to related firms**—Sales made to related firms. Report transfers to related firms at fair market value even if this is not how these transactions are valued in your own books and records. This would commonly be estimated based on the company's commercial sales of similar product or market knowledge.

**Costs and expenses**—Include costs and expenses associated with all reported net sales (i.e., for both domestic and export commercial sales, internal consumption, and transfers to related firms). If any freight costs were removed from net sales values, ensure the associated costs are removed from the applicable cost/expense line.

*Inputs from related suppliers*—Any inputs purchased from related suppliers should be reported in a manner consistent with your firm's accounting books and records.

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the financial data, as Commission staff may contact your firm regarding questions on the financial data. The Commission may also request that your company submit copies of the supporting documents/records (financial statements, including internal profit-and-loss statements for the division or product group that includes phosphate esters, as well as specific statements and worksheets) used to compile these data.

## III-9a. **Operations on phosphate esters**.—Continued

Quantity (in metric tons) and value (in \$1,000)				
	Years			
Item	2021	2022	2023	
Net sales quantities:				
Commercial sales				
Internal consumption				
Transfers to related firms				
Total net sales quantities	0	0	0	
Net sales values: Commercial sales				
Internal consumption				
Transfers to related firms				
Total net sales values	0	0	0	
Cost of goods sold (COGS): Raw materials				
Direct labor				
Other factory costs				
Total COGS	0	0	0	
Gross profit or (loss)	0	0	0	
SG&A expenses				
Operating income (loss)	0	0	0	
Other expenses and income: Interest expense				
All other expense items				
All other income items				
Net income or (loss) before income taxes	0	0	0	

III-9b.	<u>Financial data reconciliation</u> Certain line items from question III-9a, including total net sales
	quantities and values, total COGS, gross profit (or loss), operating profit (or loss), and net
	income (or loss), have been calculated based on the data submitted for other line items. Are the
	data in these calculated line items correct according to your firm's financial records ignoring
	non-material differences that may arise due to rounding?

		If noIf the calculated line items do not show the correct data, please double check the feeder data for data entry errors and revise.  Also, check signs accorded to the post operating income line items. The two expense line items should report positive numbers (i.e., expenses are positive, and incomes or reversals are negative in these lines – instances of the latter should be rare in these lines). The income line item should also, in most instances, be a positive number (i.e., income is positive, and expenses or reversals are negative in this line).
Yes	No	If, after reviewing and potentially revising the feeder data your firm has provided, the differences between your records and the calculated line items persist, please identify and discuss the differences in the space below.

III-9c. Raw materials.—Please report the share of total raw material costs in 2023 (reported in III-9a) for the following raw material inputs:

		Procureme	ent method
Input	Share of total raw material costs (percent)	Primarily produced by your firm	Primarily purchased by your firm
Phosphorous oxychloride			
Alcohol or epoxide			
Other raw material inputs <sup>1</sup>			
Total (should sum to 100 percent)	0.0		
<sup>1</sup> Please list any major other raw material costs for which each account:	inputs here and provide th	ne share of the tot	tal raw material

III-9d. <u>Depreciation expense</u>.—Please report the amount of depreciation expense that is included within the reported financial results at question III-9a.

	Years		
Item	2021	2022	2023
Depreciation expense (in \$1,000)			

III-9e.	<u>Depreciation expense classification</u> .—Please indicate the line item(s) within question III-9a (e.g., other factory costs, SG&A expenses, etc.) that include the depreciation expense reported above.

III-10a. Nonrecurring items (charges and gains) included in the phosphate esters financial results.—
Please report all material (significant) nonrecurring items (charges and gains) that are included in the reported results at question III-9a. If a nonrecurring item that is not product-specific was allocated to the results at question III-9a, please report the allocated value, below, rather than the aggregate amount.

Note: The Commission's objective here is to gather information on <u>material (significant)</u> nonrecurring items which impacted the reported financial results for phosphate esters in question III-9a.

	Years		
Item	2021	2022	2023
		Value ( <i>\$1,000</i> )	
Nonrecurring item 1			
Nonrecurring item 2			
Nonrecurring item 3			
Nonrecurring item 4			
Nonrecurring item 5			
Nonrecurring item 6			
Nonrecurring item 7			

III-10b. Nonrecurring items (charges and gains) included in the phosphate esters financial results.—In this table, please provide a brief description of each nonrecurring item reported above and indicate the specific line item within question III-9a in which the nonrecurring item is classified.

	Description of the nonrecurring item	Location (i.e., line item) within question III-9a
Nonrecurring item 1		
Nonrecurring item 2		
Nonrecurring item 3		
Nonrecurring item 4		
Nonrecurring item 5		
Nonrecurring item 6		
Nonrecurring item 7		

<u>records of the company</u> .—If non-recurring items were reported in question III-10 above, please
identify where your company recorded these items in your accounting books and records in the
normal course of business, just as responses to question III-10 identify the specific line items in
question III-9a where these items are reported.

110	Droducorc'	Questionnaire -	Dhacabata	Ectore	(Droliminary)
U.S.	FIUUULEIS	Questionnan e -	· PHOSDHate	ESTELS	(Freiiiiiiiai v

III-12a. <u>Asset values</u>.—Report the total assets (i.e., <u>both current and long-term assets</u>) associated with the production, warehousing, and sale of phosphate esters. If your firm does not maintain some or all of the specific asset information necessary to calculate total assets for phosphate esters in the normal course of business, please estimate this information based upon a method (such as production, sales, or costs) that is consistent with relevant cost allocations used in question III-9a.

**Note:** Total assets should reflect the <u>net amount of assets</u> (i.e., after any accumulated depreciation and allowances deducted) and should be <u>allocated to phosphate esters</u> if these assets are also related to other products.

Value (in \$1,000)					
	Years				
Item	2021	2022	2023		
Total assets (net)					

	Total assets (net)							
III-12b.	II-12b. <u>Description of asset values</u> .—Please provide explanations for any substantial changes in t asset value during the period; e.g., due to write-offs, major purchases, and revaluations. A describe the main asset categories (both current and long-term) included in the above res							
III-13a.	Capital expenditures and rescapital expenditures and resc	_						
		Value ( <i>in \$1,000</i> )						
			Years					
	Item	2021	2022	2023				
	Capital expenditures							
	R&D expenses							
III-13b.	Description of reported capital expenditures.—Please describe the nature, focus, and significance of your firm's reported capital expenditures. If no capital expenditure data were reported, please explain the reason.							
III-13c.	Description of reported R&D or your firm's reported R&D expe	<del>-</del>	cribe the nature, focus,	, and significance of				

III-14a. <u>Data consistency and reconciliation</u>.—The quantities and values of total net sales reported in question III-9a should reconcile with the total shipments reported in question II-8 (including export shipments) for the annual-year periods as long as they are reported on the same calendar-year basis.

If the calculated fields below return values other than zero (i.e., "0") this indicates the total net sales quantities and values do not match the total shipments quantities and values.

	Years				
Reconciliation	2021	2022	2023		
Quantity: Trade data from question II-8 (lines D, F, H, and J) less financial total net sales quantity data from question III-9a, = zero ("0").	0	0	0		
Value: Trade data from question II-8 (lines E, G, I, and K) less financial total net sales value data from question III-9a, = zero ("0").	0	0	0		

alue data	from question	III-9a, = zero ("	0").	0	0		0
	Is the financial data in question III-9a reported on a calendar-year basis?  Yes—Complete question III-14b. No— Continue to question III-15.						
	III-14b. Data consistency and reconciliation (calendar-year based financial data).—Do the data in question III-9a reconcile with the data in question II-8 (i.e., the calculated fields are returning zeros in the table above) for all periods?						
	Yes No If no, please explain.						

Other

III-15.	. <u>Effects of imports on investment</u> .—Since January 1, 2021, has your firm experienced any accordance effects on its return on investment or the scale of capital investments as a result of imports of phosphate esters from China?				
	No	Yes	If yes, my firm has experienced actual negative effects as follows:		
		(chec	k as many as appropriate)	(please describe)	
			Cancellation, postponement, or rejection of expansion projects		
			Denial or rejection of investment proposal		
			Reduction in the size of capital investments		
			Return on specific investments negatively impacted		

III-16.	Effects of imports on growth and development.—Since January 1, 2021, has your firm
	experienced any actual negative effects on its growth, ability to raise capital, or existing
	development and production efforts (including efforts to develop a derivative or more advanced
	version of the product) as a result of imports of phosphate esters from China?

version o	in the pro	adet, as a result of imports of	phosphate esters from enima.		
No	Yes				
		If yes, my firm has experienced actual negative effects as follows:			
	(chec	k as many as appropriate)	(please describe)		
		Rejection of bank loans			
		Lowering of credit rating			
		Problem related to the issue of stocks or bonds			
	Ability to service debt				
		Other			

U.S. Pr	oducers' Qı	uestionnai	re – <b>Phosphate Esters (Preliminary)</b>	age 3				
III-17.	<u>Anticipated effects of imports</u> .—Does your firm anticipate any negative effects due to imports of phosphate esters from China?							
	No	Yes	If yes, my firm anticipates negative effects as follows:					
III-18.	governme performar your respo	Effects on financial performance of COVID-19.—Has the COVID-19 pandemic, or any government actions taken to contain the spread of the COVID-19 virus, affected the financial performance of your firm's operations on phosphate esters as reported in question III-9a? In your response, please include the duration and timing of any impacts as they relate to your firm's financial performance.						
	No	Yes	If yes, please describe these effects.					
III-19.	III for whice	ch a narrat	.—If your firm would like to further explain a response to a question in tive box was not provided, please note the question number and the pace provided below. Please also use this space to highlight any issues g the data in this section.					

#### PART IV.--PRICING AND MARKET FACTORS

Further information on this part of the questionnaire can be obtained from John Benedetto (202-205-3270, john.benedetto@usitc.gov).

IV-1. <u>Contact information</u>.--Please identify the individual that Commission staff may contact regarding the confidential information submitted in Part IV.

Name	
Title	
Email	
Telephone	

### **PRICE DATA**

- IV-2. This question requests quarterly quantity and value data for your firm's commercial shipments to unrelated U.S. customers since January 1, 2021 of the following products produced by your firm.
  - **Product 1.--** Tris (2-chloroisopropyl) phosphate (TCPP), bulk liquid, in drums, tanks or other bulk containers greater than 250 kg capacity.
  - **Product 2.**—Tris (1,3-dichloroisopropyl) phosphate (TDCP), bulk liquid, in drums, tanks or other bulk containers greater than 250 kg capacity.

Please note that values should be <u>f.o.b.</u>, <u>U.S.</u> <u>point of shipment</u> and should not include U.S.-inland transportation costs. Values should reflect the *final net* amount paid to your firm (i.e., should be net of all deductions for discounts or rebates).

IV-2a. During January 2021-December 2023, did your firm produce and sell to unrelated U.S. customers any of the above listed products (or any products that were competitive with these products)?

YesPlease complete the following pricing data table as appropriate.
NoSkip to question IV-3.

IV-2b. <u>Price data</u>.--Report below the quarterly price data<sup>1</sup> for pricing products<sup>2</sup> produced and sold by your firm.

Report data in *metric tons* and *actual dollars* (not \$1,000s).

(Quantity in metric tons, value in dollars)							
	Produ	ict 1	Product 2				
Period of shipment	Quantity	Value	Quantity	Value			
2021:							
January-March							
April-June							
July-September							
October-December							
2022:							
January-March							
April-June							
July-September							
October-December							
2023:							
January-March							
April-June							
July-September							
October-December							

<sup>&</sup>lt;sup>1</sup> Net values (i.e., gross sales values less all discounts, allowances, rebates, prepaid freight, and the value of returned goods), f.o.b. your firm's U.S. point of shipment. Please subtract any discounts, rebates, and returns from the quarter in which the sale occurred.

**Note.**—If your firm's product does not exactly meet the product specifications but is competitive with the specified product, provide a description of your firm's product. Also, please explain any anomalies in your firm's reported pricing data.

Product 1:

Product 2:

<sup>&</sup>lt;sup>2</sup> Pricing product definitions are provided on the first page of Part IV.

IV-2c.	Price data checklist Please check that the pricing data in question IV-2b have been correctly
	reported.

	Are the price data reported above:	√ if Yes			
	In actual dollars (not \$1,000s) and metric tons?				
	Valued f.o.b. U.S. point of shipment (i.e., exclude U.S. inland transportation costs)?				
	Reported net of all discounts, rebates, and returns (deducted from the quarter in which the original sale occurred)?				
	Reported for commercial U.S. shipments only (i.e., exclude internal consumption, transfers, and exports)?				
	Less than or equal to the quantities and values reported in part II for commercial U.S. shipments in each period?				
	Explanation(s) for any boxes not checked:				
IV-2d. Pricing data methodologyPlease describe the method and the kinds of documents/r that were used to compile your price data.					

Note: As requested in Part I of this questionnaire, please keep all supporting documents/records used in the preparation of the price data, as Commission staff may contact your firm regarding questions on the price data. The Commission may also request that your company submit copies of the supporting documents/records (such as sales journal, invoices, etc.) used to compile these data.

115	Droducars'	Questionnaire -	Phoenhata Fe	ters (Preliminary
U.S	. Producers	Questionnaire –	Phosphate es	ters (Preliminary

IV-3.	Price settingHow does your firm determine the prices that it charges for sales of phosphate
	esters (check all that apply)?

Transaction by transaction	Contracts	Set price lists	Other	If other, describe

IV-4. <u>Discount policy</u>.--Please indicate and describe your firm's discount policies (*check all that apply*).

Quantity discounts	Annual total volume discounts	No discount policy	Other	Describe

IV-5. **Pricing terms.**—On what basis are your firm's prices of domestic phosphate esters usually quoted *(check one)*?

Delivered	F.o.b.	If f.o.b., specify point

IV-6. <u>Contract versus spot</u>.--Approximately what shares of your firm's sales of its U.S.-produced phosphate esters in 2023 were on the basis of (1) short-term contracts, (2) annual contracts, (3) long-term contracts, and (4) spot sales?

	Type of sale					
ltem	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)	Spot sales (for a single delivery)	Total (should sum to 100.0%	d o
Share of 2023 sales	%	%	%	%	0.0	%

IV-7. <u>Contract provisions.</u>--Please fill out the table regarding your firm's typical sales contracts for U.S.-produced phosphate esters (or check "not applicable" if your firm does not sell on a short-term, annual and/or long-term contract basis).

Typical sales contract provisions	Item	Short-term contracts (multiple deliveries for less than 12 months)	Annual contracts (multiple deliveries for 12 months)	Long-term contracts (multiple deliveries for more than 12 months)	
Average contract duration	No. of days		365		
Price renegotiation	Yes				
(during contract period)	No				
	Quantity				
Fixed quantity and/or price	Price				
3.1.5, 5.1 p.1.55	Both				
Indexed to raw	Yes				
material costs <sup>1</sup>	No				
Not applicab	le				
<sup>1</sup> Please identify the indexes used:					

IV-8. <u>Lead times.</u>--What share of your firm's sales of its U.S.-produced phosphate esters were from inventory and produced to order, and what was the typical lead time between a customer's order and the date of delivery for your firm's sales of its U.S.-produced phosphate esters?

Source	Share of 2023 sales	Lead time (Average number of days)
From inventory	%	
Produced to order	%	
Total (should sum to 100.0%)	0.0 %	

(a)	Who generally	arranges the transportation to your firm's customers'	locations?
	Your firm	Purchaser (check one)	

(b) Indicate the approximate percentage of your firm's sales of phosphate esters that are delivered the following distances from its production facility.

Distance from production facility	Share
Within 100 miles	%
101 to 1,000 miles	%
Over 1,000 miles	%
Total (should sum to 100.0%)	0.0 %

IV-10. <u>Geographical shipments.--</u>In which U.S. geographic market area(s) has your firm sold its U.S.-produced phosphate esters since January 1, 2021 (check all that apply)?

Geographic area	√ if applicable
NortheastCT, ME, MA, NH, NJ, NY, PA, RI, and VT.	
Midwest.–IL, IN, IA, KS, MI, MN, MO, NE, ND, OH, SD, and WI.	
Southeast.—AL, DE, DC, FL, GA, KY, MD, MS, NC, SC, TN, VA, and WV.	
Central Southwest.—AR, LA, OK, and TX.	
Mountains.–AZ, CO, ID, MT, NV, NM, UT, and WY.	
Pacific Coast.–CA, OR, and WA.	
Other.—All other markets in the United States not previously listed, including AK, HI, PR, and VI.	

IV-11.	<u>Inland transportation costs.</u> —What is the approximate percentage of the cost of	U.Sproduced
	phosphate esters that is accounted for by U.S. inland transportation costs?	percent

IV-12. <u>End uses</u>.--List the end uses of the phosphate esters that your firm manufactures. For each enduse product, what percentage of the <u>total cost</u> is accounted for by phosphate esters and other inputs?

	Share of total cost	Total	
			(should sum to
End-use product	Phosphate esters	Other inputs	100.0% across)
	%	%	0.0 %
	%	%	0.0 %
	%	%	0.0 %

IV-13	. <u>Substitutes</u> Can other products be substituted for phosphate esters?						
	☐ No	YesPlease fill out t	he tak	le.			
		End use in which this			nanges in the price of this substitute ed the price for phosphate esters?		
	Substitute	substitute is used	No	Yes	Explanation		
1.							
2.							
3.							

IV-14. <u>Demand trends.</u>-- Has demand within the United States and outside of the United States (if known) for phosphate esters steadily increased, fluctuated but ended higher, not changed, fluctuated but ended lower, or steadily decreased since January 1, 2021? Explain any trends and describe the principal factors that have affected these changes in demand.

Select one box per row.

Market	Steadily increase	Fluctuate up	No change	Fluctuate down	Steadily decrease	Explanation and factors
Within the United States						
Outside the United States						

U.S. Pro	oducers' Qı	uestionnai	re – Phosphate Esters (Preliminary) Page 4	5
IV-15.		_	Have there been any significant changes in the product range, product mix, sphate esters since January 1, 2021?	
	No	Yes	If yes, please describe and quantify if possible.	
IV-16.		<del>-</del>	the phosphate esters market subject to business cycles, either during the ? If yes, describe.	
	No	Yes	If yes, please describe, including any changes since January 1, 2021.	
IV-17.		to phosp	<u>etition</u> Is the phosphate esters market subject to conditions of competitio hate esters other than the business cycles described in the previous scribe.	'n
	No	Yes	If yes, please describe, including any changes since January 1, 2021.	
IV-18.	at any tim "controlle delivering	e since Jai d order er less than	Has your firm refused, declined, or been unable to supply phosphate ester nuary 1, 2021 (examples include placing customers on allocation or ntry," declining to accept new customers or renew existing customers, the quantity promised, being unable to meet timely shipment commitment in operations listed in II-2a, etc.)?	
	No	Yes	If yes, please describe, including the reason, timing, and duration of the constraint.	
		l		

IV-19. Raw materials.-- Have phosphate esters raw material prices steadily increased, fluctuated but ended higher, not changed, fluctuated but ended lower, or steadily decreased since January 1, 2021?

Select one box per row.

Steadily increase	Fluctuate up	No change	Fluctuate down	Steadily decrease	Explain, noting how raw material price changes have affected your firm's selling prices for phosphate esters.

IV-20. <u>Interchangeability</u>.—How often are phosphate esters produced in the United States and in other countries interchangeable (i.e., can they physically be used in the same applications)?

Please indicate A, F, S, N, or 0 in the table below:

- A = the products from a specified country-pair are *always* interchangeable
- F = the products are *frequently* interchangeable
- S = the products are *sometimes* interchangeable
- N = the products are *never* interchangeable
- 0 = *no familiarity* with products from a specified country-pair

Country-pair	China	Other countries			
United States					
China					
For any country-pair producing phosphate esters that is <i>sometimes</i> or <i>never</i> interchangeable, identify the country-pair and explain the factors that limit or preclude the interchangeable use of phosphate esters produced in the countries:					

110	Droducorc'	Questionnaire -	Dhacabata	Ectore	(Droliminary)
U.S.	ribuuceis	Questionnane -	riiospiiate	ESTELS	(Freiiiiiiiiai vi

IV-21.	Factors other than price.—How often are differences other than price (e.g., quality, availability,
	transportation network, product range, technical support, etc.) between phosphate esters
	produced in the United States and in other countries a significant factor in your firm's sales of
	the products?

Please indicate A, F, S, N, or 0 in the table below:

IV-22.

A = such differences are *always* significant

F = such differences are *frequently* significant

S = such differences are *sometimes* significant

N = such differences are *never* significant

0 = no familiarity with products from a specified country-pair

United States  China  For any country-pair for which factors other than price are always or frequently a signification in your firm's sales of phosphate esters, identify the country-pair and the relevant factors other than price, and report the advantages or disadvantages imparted by such factors:  Sole of section 301 tariffs Did the tariffs on Chinese-origin products under section 301, nanges in these tariffs, have an impact on the phosphate esters market in the United Staticular country and since January 2021?  Yes  No  Don't know	Country-pair		China	Other countries
For any country-pair for which factors other than price are <i>always</i> or <i>frequently</i> a significator in your firm's sales of phosphate esters, identify the country-pair and the relevant factors other than price, and report the advantages or disadvantages imparted by such factors:    Ole of section 301 tariffs Did the tariffs on Chinese-origin products under section 301, hanges in these tariffs, have an impact on the phosphate esters market in the United Starluding any effects on phosphate esters cost, price, supply, and/or demand, since January 221?	Jnited States			
actor in your firm's sales of phosphate esters, identify the country-pair and the relevant actors other than price, and report the advantages or disadvantages imparted by such actors:    Ole of section 301 tariffs Did the tariffs on Chinese-origin products under section 301, langes in these tariffs, have an impact on the phosphate esters market in the United Stackluding any effects on phosphate esters cost, price, supply, and/or demand, since January 221?	China			
· 	actors other th actors:	nan price, and	report the advantages or	disadvantages imparted by such
	cluding any eff	tariffs, have	an impact on the phospha	te esters market in the United Sta
	cluding any eff 21?	tariffs, have a	an impact on the phospha ohate esters cost, price, su	te esters market in the United Sta pply, and/or demand, since Janua

IV-23. <u>Customer identification</u>.--List the names and contact information for your firm's 10 largest U.S. customers for phosphate esters since January 1, 2021. Indicate the share of the quantity of your firm's U.S. shipments of phosphate esters that each of these customers accounted for in 2023.

Cu	stomer's name	Contact person	Email	Telephone	City	State	Share of 2023 sales (%)
1							
2							
3							
4							
5							
6							
7							
8							
9							
10							

IV-24.	Com	petition	from	im	ports

(a) <u>Lost revenue</u>.--Since January 1, 2021: To avoid losing sales to competitors selling phosphate esters from China, did your firm:

Item	No	Yes
Reduce prices		
Roll back announced price increases		

(b) <u>Lost sales</u>.--Since January 1, 2021: Did your firm lose sales of phosphate esters to imports of this product from China?

No	Yes	

(c) The submission of lost sales/lost revenue allegations is to be completed only by NON-PETITIONERS.

If your firm indicated "yes" to any of the above, your firm can provide the Commission with additional information by downloading and completing the lost sales/lost revenues worksheet at <a href="http://usitc.gov/trade\_remedy/question.htm">http://usitc.gov/trade\_remedy/question.htm</a>. Note that the Commission may contact the firms named to verify the allegations reported.

Is your firm submitting the lost sales/lost revenues worksheet?

No—Please explain.
Yes—Please complete the worksheet and submit via the <b>Commission's secure submission portal by clicking on the following link</b> : <a href="https://usitc.gov/qportal">https://usitc.gov/qportal</a> . (PIN: FIRE).

IV-25. Other explanations.--If your firm would like to further explain a response to a question in Part IV for which a narrative response box was not provided, please note the question number and the explanation in the space provided below. Please also use this space to highlight any issues your firm had in providing the data in this section.

1			

#### PART V.--ADDITIONAL PRODUCT INFORMATION

Further information on this part of the questionnaire can be obtained from Celia Feldpausch (202-205-2387, celia.feldpausch@usitc.gov). Supply all data requested on a calendar-year basis.

- V-1. Comparability of different phosphate esters with each other.--For each of the following indicate whether listed products are: fully comparable or the same (i.e., have no differentiation between them); mostly comparable or similar; somewhat comparable or similar; never or not-at-all comparable or similar; or no familiarity with products.
  - F: fully comparable or the same, *i.e.*, have no differentiation between them;

M: mostly comparable or similar;

S: somewhat comparable or similar;

N: never or not-at-all comparable or similar; or

0: no familiarity with products.

(a) <u>Physical Characteristics and End Uses</u>.--The differences and similarities in the physical characteristics and end uses.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their physical characteristics and uses:
TCPP <u>vs.</u> TDCP		
TCPP <u>vs.</u> TEP		
TDCP <u>vs.</u> TEP		

(b) Interchangeability.--The ability to substitute the products in the same application.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <u>interchangeability</u> :
TCPP <u>vs.</u> TDCP		
TCPP <u>vs.</u> TEP		
TDCP <u>vs.</u> TEP		

## V-1. Comparability of different phosphate esters with each other.--Continued

F: fully comparable or the same, i.e., have no differentiation between them;

M: mostly comparable or similar;

S: somewhat comparable or similar;

N: never or not-at-all comparable or similar; or

0: no familiarity with products.

(c) <u>Channels of distribution</u>.--Channels of distribution/market situation through which the products are sold (i.e., sold direct to end users, through wholesaler/distributors, etc.).

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <u>channels of distribution</u> :
TCPP <u>vs.</u> TDCP		
TCPP <u>vs.</u> TEP		
TDCP <u>vs.</u> TEP		

(d) <u>Manufacturing facilities, production processes, and production employees</u>.--Whether manufactured in the same facilities, from the same inputs, on the same machinery and equipment, and using the same employees.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their manufacturing facilities, production processes, and production employees:
TCPP <u>vs.</u> TDCP		
TCPP <u>vs.</u> TEP		
TDCP <u>vs.</u> TEP		

# V-1. Comparability of different phosphate esters with each other.--Continued

F: fully comparable or the same, i.e., have no differentiation between them;

M: mostly comparable or similar;

S: somewhat comparable or similar;

N: never or not-at-all comparable or similar; or

0: no familiarity with products.

(e) <u>Customer and producer perceptions</u>.--Perceptions as to the differences and/or similarities in the market (*e.g.*, sales/marketing practices).

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their customer and producer perceptions:
TCPP <u>vs.</u> TDCP		
TCPP <u>vs.</u> TEP		
TDCP <u>vs.</u> TEP		

(f) **Price**.--Whether prices are comparable or differ between the products.

Product-pair	Comparison	Please provide a narrative discussion for the comparability ratings you provided in terms of their <i>price</i> :
TCPP <u>vs.</u> TDCP		
TCPP <u>vs.</u> TEP		
TDCP <u>vs.</u> TEP		

# **HOW TO FILE YOUR QUESTIONNAIRE RESPONSE**

This questionnaire is available as a "fillable" form in MS Word format on the Commission's website at:

https://usitc.gov/reports/active import injury questionnaires.

**Please do not attempt to modify the format or permissions of the questionnaire document**. Please submit the completed questionnaire using one of the methods noted below. If your firm is unable to complete the MS Word questionnaire or cannot use one of the electronic methods of submission, please contact the Commission of further instructions.

• <u>Upload via Commission's secure submission portal</u>.— The questionnaire must be uploaded in two formats: (1) a Microsoft Word 97-2003 document; and (2) a PDF copy of the complete questionnaire with a signature on the first page. Please include any attachments at the end of the PDF (e.g., APO certification, additional comments, etc.).

Web address: https://usitc.gov/qportal Pin: FIRE

• E-mail.— E-mail the MS Word questionnaire to <u>celia.feldpausch@usitc.gov</u>; include a PDF copy of the complete questionnaire with a signature on the first page. Submitters are strongly encouraged to encrypt nonpublic documents that are electronically transmitted to the Commission to protect your sensitive information from unauthorized disclosure. The USITC secure submission portal and the Electronic Document Information System (EDIS) use Federal Information Processing Standards (FIPS) 140-2 cryptographic algorithms to encrypt data in transit. Submitting your nonpublic documents by a means that does not use these encryption algorithms (such as by email) may subject your firm's nonpublic information to unauthorized disclosure during transmission. If you choose a non-encrypted method of electronic transmission, the Commission warns you that the risk of such possible unauthorized disclosure is assumed by you and not by the Commission.

**If your firm** <u>does not </u>**produce this product**, please fill out page 1, print, sign, and submit a scanned PDF copy via the Commission's secure submission portal or email.

<u>Parties to this proceeding</u>.— If your firm is a party to this proceeding, it is required to serve a copy of the completed questionnaire on parties to the proceeding that are subject to administrative protective order (see 19 CFR § 207.7). A list of such parties may be obtained from the Commission's Secretary (202-205-1802). A certificate of service must accompany the completed questionnaire you submit (see 19 CFR § 207.7). Service of the questionnaire must be made in paper form.